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a b s t r a c t
Noroviruses are the most common cause of acute gastroenteritis in humans. Development of an effective
vaccine is required for reducing their outbreaks. In order to develop a GI norovirus vaccine, Newcastle
disease virus vectors, rLaSota and modiﬁed rBC, were used to express VP1 protein of Norwalk virus. Co-
expression of VP1 and VP2 proteins by Newcastle disease virus vectors resulted in enhanced expression
of Norwalk virus VP1 protein and self-assembly of VP1 protein into virus-like particles. Furthermore, the
Norwalk virus-speciﬁc IgG response induced in mice by Newcastle disease virus vectors was similar to
that induced by baculovirus-expressed virus-like particles in mice. However, the modiﬁed rBC vector in
the presence of VP2 protein induced signiﬁcantly higher levels of cellular and mucosal immune
responses than those induced by baculovirus-expressed VLPs. These results indicate that Newcastle
disease virus has great potential for developing a live Norwalk virus vaccine by inducing humoral,
cellular and mucosal immune responses in humans.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Human noroviruses are the most frequent cause of viral gastro-
enteritis in people of all ages (Scallan et al., 2011). Noroviruses are
members of the family Caliciviridae (Green, 2013). Genus Norovirus is
divided into 6 genogroups (GI–GVI). The GI and GII genogroups are
the most important for human infection. Their genome consists of a
linear, positive-sense, single-stranded RNA molecule of 7.6 kb with a
50 untranslated region (UTR), three open reading frames (ORFs), a
30UTR, and a poly(A) tail. ORF1 encodes a large nonstructural
polyprotein. ORF2 and ORF3 encode structural proteins, the major
capsid protein (VP1) and a minor capsid protein (VP2), respectively.
VP1 protein is the major immunogenic protein of noroviruses (Ball
et al., 1998). Expression of VP1 alone has been shown to produce self-
assembled norovirus-like particles (VLPs) that are morphologically
and antigenically similar to native virions (Jiang et al., 1992).
There is a need to develop an effective vaccine against norovirus
infection, but the inability of noroviruses to grow in cell culture
systems has hindered the development of effective vaccines. Only
recently, a cell culture systemwas successfully developed by infecting
a human norovirus in human B cells (Jones et al., 2014). To circumvent
this obstacle, VLPs produced by the baculovirus expression system
has been used as norovirus vaccine candidates. Norwalk virus (NV, GI)
VLPs have shown to be immunogenic when delivered through
intranasal, oral, or parenteral route in mice (El-Kamary et al., 2010;
Estes et al., 2000; Guerrero et al., 2001; Harrington et al., 2002;
Lindesmith et al., 2005). A NV VLP vaccine was further evaluated in a
phase II human trial (Atmar et al., 2011). Two doses of this VLP
candidate vaccine reduced the rate of symptomatic infection by 47%
and the overall rate of infection by 26%. Serum blockade antibody
titers above 200 were associated with a 72% reduction in frequency of
illness and a 57% reduction in infection, providing evidence that pre-
challenge blockade antibody titers correlated to protection following
vaccination and challenge in human volunteers. However, cross-
challenge studies suggest that a multivalent GI and GII vaccine
platform is required for broad protection (LoBue et al., 2006).
Intramuscular immunization of a bivalent formulation including GII
and consensus VLPs induced higher antibody levels than the intra-
nasal route of immunization (Parra et al., 2012). In addition, large-
scale manufacture of baculovirus VLP vaccines has not been cost-
effective and the protective efﬁcacy of baculovirus VLP vaccines
against a broad range of norovirus genogroups and genotypes needs
to be improved. For effective delivery and large-scale manufacture of
VLPs, alternative expression and delivery systems, such as Venezuelan
equine encephalitis and vesicular stomatitis viruses have been
evaluated (Baric et al., 2002; Guo et al., 2008; Ma and Li, 2011).
However, safety concerns regarding systemic spread causing viremia
and potential neurovirulence are associated with these viruses
(Bukreyev and Collins, 2008). Therefore, there is a great need to
evaluate additional viral vectors for an effective norovirus vaccine.
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Newcastle disease virus (NDV) belongs to the genus Avulavirus in
the family Paramyxoviridae. The genome of NDV is a single-stranded,
negative-sense RNA (Samal, 2011). NDV isolates vary greatly in their
pathogenicity for chickens, and are categorized into three main
pathotypes: lentogenic (avirulent), mesogenic (moderately virulent),
and velogenic (highly virulent) (Alexander, 1989). Recombinant lento-
genic and mesogenic NDV strains have been evaluated as vaccine
vectors for animal and human pathogens (Bukreyev and Collins,
2008). Recently, we have evaluated recombinant NDV (rNDV) as a
vaccine vector for norovirus (Kim et al., 2014). rNDV expressing the
VP1 protein of genogroup (G) II genotype 4 strain elicited norovirus-
speciﬁc humoral, mucosal, and cellular immune responses in mice,
indicating that NDV has the potential to be used as a live viral vaccine
against norovirus infection.
The rapid evolution of norovirus genotypes and changing of
glycan speciﬁcities provide new challenges to norovirus vaccine trials
(Ramani et al., 2014). Cross-challenge studies suggest that a multi-
valent GI and GII vaccine platform is required for broad protection
(LoBue et al., 2006). Although our previous study showed expression
of VP1 protein of norovirus genotype II.4 strain using rNDV vectors, it
will be necessary to formulate NDV vectored vaccines expressing VP1
proteins of multiple genotypes for broad protection using a prime-
boost approach. Therefore, in this study, we have evaluated whether
rNDV can also be used as a vaccine vector for genogroup I (GI) viruses,
which are the most common cause of water-borne norovirus
outbreaks (Matthews et al., 2012). VP1 protein of the prototype
strain, NV was expressed by two different rNDV vectors, since
expression of VP1 protein and induction of immune response in
mice can be affected by the type of rNDV vector (Kim et al., 2014).
Results
Generation of rNDVs expressing NV VP1 protein
The ORF2 (1593 nt) of norovirus strain Norwalk virus (Hu/NV/
Norwalk virus/1968/US) (Fernandez-Vega et al., 2004) was inserted
into cDNAs encoding the complete antigenomic RNAs of NDV strain
rLaSota (conventional vector) and a modiﬁed rNDV for comparison of
the expression levels of VP1 protein (Fig. 1). NDV strain tLaSota is an
avirulent lentogenic virus that has been widely used as a vector for
vaccine development. The modiﬁed vector contained the cDNA of the
mesogenic NDV strain Beaudette C (BC) in which the sequence of the
F protein cleavage site and HN protein was modiﬁed to those of
lentogenic strain LaSota (rBCm). rNDVs were readily recovered using
our standard procedure (Huang et al., 2001). The correct sequence of
the NV insert in each recovered virus was conﬁrmed by RT-PCR and
sequence analysis.
Expression of the VP1 protein by rNDV vectors was evaluated in
DF1 cells infected with rLaSota-NV ORF2, rBCm-NV ORF2, or their
Fig. 1. Generation of rNDVs containing NV ORF2 and production of VP1 protein by rNDVs and in vitro multicycle growth of parental and vaccine viruses in DF1 cells. NV ORF2
alone (A) and ORF2, ORF3, and 30UTR together (B) were ﬂanked by the gene-start and gene-end signals of NDVs and inserted into the intergenic region between the P and M
genes in a full-length antigenomic cDNA of NDVs. (C) DF1 cells were infected with each virus at MOI 1, and cell lysates were collected at 24 h post-infection for Western blot
analysis. VP1 (58 kDa) and VP2 (28 kDa) proteins were detected using VP1 speciﬁc monoclonal antibody and VP2 speciﬁc antipeptide antiserum, respectively. NDV HN
protein was detected using a monoclonal antibody. Each ﬁgure represents three independent experiments. (D) Detection of NV VP1 in allantoic ﬂuid of chicken embryonated
eggs. Each allantoic ﬂuid was harvested at 72 h post-infection and clariﬁed by centrifugation at 3000 rpm for 10 min. This ﬁgure represents three independent experiments.
(E) DF1 cells were infected with parental or each vaccine virus at an MOI of 0.01. Exogenous protease was provided in the infected cells. The viral titers were determined by
limiting dilution on DF1 cells. Results are represented as mean7SD for the mean of two independent experiments.
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parental viruses by Western blot using a monoclonal antibody to
VP1 (Parra et al., 2013). rLaSota-NV ORF2 and rBCm-NV ORF2
expressed relatively low levels of VP1 protein (58 kDa) in DF1 cells
(Fig. 1C). This indicates that modiﬁcation in the transcription unit
of VP1 ORF2 would be necessary to enhance its expression levels,
since the level of VP1 expression can greatly affect the immuno-
genicity in vivo (Kim et al., 2014). Previously, the expression of VP1
protein by baculovirus in insect cells was enhanced by the
presence of the ORF3 and NV 30UTR (Bertolotti-Ciarlet et al.,
2003). However, the contribution of minor structural protein VP2
to expression level of VP1 protein and immune response of
norovirus VLP is not well understood. Therefore, we have further
evaluated whether VP2 protein can affect expression of VP1
protein and immune response in mice. A transcription cassette
containing ORF2, ORF3, and 30UTR (ORF2þ3þ30UTR, 2297 nt) was
placed into cDNAs of rLaSota and rBCm vectors (Fig. 1B). Western
blot analysis conﬁrmed the expression of the VP2 protein by rNDV
vectors and showed enhanced expression of VP1 protein in the
presence of ORF3 and 30UTR (Fig. 1C). Speciﬁcally, rBCm expressed
higher levels of VP1 protein than rLaSota (Lanes 7 and 8). We then
compared the expression levels of VP1 protein by rNDVs in the
allantoic ﬂuid of embryonated chicken eggs (Fig. 1D). Similarly,
both rNDV vectors containing ORF2þ3þ30UTR produced higher
levels of VP1 protein in allantoic ﬂuid than those with only ORF2.
In vitro characterization and attenuation of rNDVs expressing VP1
protein
Growth kinetics of parental and rNDVs expressing VP1 protein in
DF1 cells was determined to evaluate the effect of insertion of
different combination of foreign genes in the NDV genome on virus
replication (Fig. 1E). DF1 cells in the presence of 10% chicken egg
allantoic ﬂuid were infected with each rNDV-VP1 at an MOI of 0.01.
Virus titers in the collected supernatants at 12-h intervals were
quantiﬁed in DF1 cells by limiting dilution. All the viruses were able
to replicate efﬁciently in the DF1 cells. In general, all of the rNDVs-NV
ORF2 and rNDVs-NV ORF2þ3þ30UTR viruses replicated less efﬁ-
ciently than their parental viruses at 24 h post-infection (hpi).
However, they replicated to high titers at 48 hpi.
Pathogenicity of rNDVs expressing NV VP1 protein was deter-
mined by the mean death time (MDT) in 9-day-old SPF embryo-
nated chicken eggs and by the intracerebral pathogenicity index
(ICPI) test in 1-day-old SPF chicks (Alexander, 1989). MDT values
for each virus were 117 h (rLaSota), 135 h (rLaSota-NV ORF2), 138 h
(rLaSota-NV ORF2þ3þ30UTR), 108 h (rBCm), 125 h (rBCm-NV
ORF2), and 132 h (rBCm-NV ORF2þ3þ30UTR). All rNDVs expres-
sing VP1 protein were more attenuated than their parental viruses.
Thus, introduction of VP1 protein to rNDV genome conferred virus
attenuation. In addition, the ICPI values of all rNDVs were 0.00,
and chicks infected with rNDVs had no apparent clinical signs
during the 8-day period of the ICPI test. This result suggests that
rNDVs expressing the VP1 protein are avirulent in chickens.
Production of NV VLPs by rLaSota and rBCm
We examined whether the NV VP1 protein produced by rNDV
vectors can self-assembled into VLPs (Fig. 2). Kinetics analysis of VP1
expression in DF1 cells infected with rLaSota-NV ORF2þ3þ30UTR
and rBCm-NV ORF2þ3þ30UTR showed that both rNDVs expressed
high levels of VP1 protein in cell culture medium at 48 hpi, indicating
gradual secretion of the VP1 protein into cell culture medium
(Fig. 2A). Since NDV grows to high titer in embryonated eggs, the
VP1 protein can also be expressed at high level in allantoic ﬂuid,
leading to efﬁcient production of VLPs. The two rNDVs containing
ORF2þ3þ30UTR grew to high titers (4108 pfu/ml) in embryonated
chicken eggs at 3 dpi (data not shown). Subsequently, kinetic analysis
conﬁrmed detection of the highest levels of VP1 protein in allantoic
ﬂuids at 3 dpi (Fig. 2A). We further veriﬁed the absence of VP1 protein
36h        48h        60h         36h          48h        60h
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Allantoic fluid
rLaSota-NV
ORF2+3+3´UTR
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Fig. 2. Characterization of VP1 protein expression and VLP production by rNDVs in DF1 cells and embryonated eggs. (A) Kinetic analysis of VP1 expression by rNDVs was
conducted in DF1 cells and in allantoic ﬂuid of chicken embryonated eggs. Cell culture medium was collected every 12 h and subjected to Western blot analysis. Allantoic
ﬂuid was harvested every 24 h post-infection and clariﬁed by centrifugation at 3000 rpm for 10 min for Western blot analysis. Each ﬁgure represents three independent
experiments. (B) Production of VLPs by rNDVs was analyzed by electron microscope. VLP suspension (10 m each) was ﬁxed in copper grids, negatively stained with 1%
ammonium molybdate, and visualized by using an electron microscope. Baculovirus-expressed VLP in Sf9 cells was included as a control. VLPs expressed by rNDVs were
prepared from infected allantoic ﬂuid of chicken embryonated eggs. Each ﬁgure represents ﬁve independent experiments.
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in sucrose puriﬁed rNDV particles by Western blot (not shown),
indicating efﬁcient secretion of VP1 protein into allantoic ﬂuid.
EM analysis was further conducted to evaluate assembly and
morphology of VLPs produced by rLaSota-NV ORF2þ3þ30UTR
and rBCm-NV ORF2þ3þ30UTR in allantoic ﬂuid of embryonated
chicken eggs compared with VLPs produced in insect cells by
baculovirus. For puriﬁcation of VLPs, allantoic ﬂuid of infected
embryonated chicken eggs was collected at 3 dpi and centri-
fuged at 3000 rpm for 10 min. The VLPs were puriﬁed by
ultracentrifugation through a 40% sucrose cushion, followed
by CsCl isopycnic gradient (1.36 g/cm3) ultracentrifugation. To
verify the morphology of VLP using the NDV system, the ORF2 of
NV was cloned into bacmids and transfected into Spodoptera
frugiperda (Sf9) cells (Invitrogen). Baculovirus-expressed VLPs
were puriﬁed and examined by EM. VLPs of approximately 35–
40 nm in diameter, similar to the size of baculovirus-expressed
VLPs were observed in embryonated egg preparations, indicat-
ing self-assembly of VP1 protein produced by the two rNDV
vectors into VLPs (Fig. 2B).
Induction of NV-speciﬁc immune responses in mice
Immunogenicity of rNDV vectors containing ORF2þ3þ30UTR
was evaluated in BALB/c female mice (5 mice per group). Mice
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Fig. 3. Antibody titers and NV-speciﬁc cellular and fecal IgA responses in mice after immunization with rNDVs and baculovirus-expressed VLPs. Mice were inoculated with
each virus and VLPs by the intranasal route for three times in a two-week interval. (A) HBGA binding blocking assay was conducted to evaluate antibody-mediated
neutralization for NV. Geometric mean titers (GMTs) for the values of the 50% blocking titer (BT50) determined by the H type 1 blocking assay. The titers of NV-speciﬁc total
IgG (B) and subtypes IgG1 (C) and IgG2a (D) were determined by ELISA against puriﬁed baculovirus-expressed VLPs. The antibody titers were deﬁned as the endpoint
dilution with a cut off signal intensity of 0.2. (E) Splenocytes from the immunized mice were stimulated with NV VLP and analyzed for the production of IFN-γ, TNF-α, and IL-
2 by the ELISPOT assay. The mean spot-forming cells (SFC)/106 cells with the error bars are shown. (F) Fecal samples were diluted in PBS, vortexed, and clariﬁed by
centrifugation. NV-speciﬁc and total IgA antibodies were determined by ELISA. The ratio between NV-speciﬁc IgA and total IgA was determined. Results are represented as
mean7SD for the mean of duplicate samples collected from 5 mice for each group. Statistical signiﬁcance was determined by ANOVA (nPo0.05).
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were immunized individually with virus (30 ml of each, 106 EID50)
by the intranasal route after inhalational anesthesia. For compar-
ison, two groups of mice were immunized with rLaSota-NV ORF2
and 30 μg of baculovirus-expressed VLPs (Fang et al., 2013). Mice
received three doses of immunization with two-week intervals.
The last group of mice was inoculated with PBS as an unvaccinated
control. All infected mice had no apparent clinical signs during the
immunization.
Serum samples were collected from pre-immunized mice and
immunized mice at 5 and 6 week postinoculation (wpi). First,
antibody-mediated neutralization for NV was determined by using
a histoblood group antigen (HBGA) binding blocking assay (Reeck
et al., 2010; Lindesmith et al., 2012). We conﬁrmed the blockade
ability of sera from mice immunized with vaccine viruses to block
NV VLP-carbohydrate interactions (Fig. 3A). Both rBCm-NV
ORF2þ3þ30UTR and rLaSota-NV ORF2þ3þ30UTR showed similar
levels of blockade ability to that of baculovirus-expressed VLPs in
mice (p40.05). NV-speciﬁc antibody response in mice was eval-
uated by determining the serum IgG antibody by ELISA (Fig. 3B). At
5 wpi, rBCm-NV ORF2þ3þ30UTR, rLaSota-NV ORF2þ3þ30UTR
and baculovirus-expressed VLPs induced similar levels of NV
speciﬁc IgG response in mice (p40.05). At 6 wpi, rBCm-NV
ORF2þ3þ30UTR and baculovirus-expressed VLPs induced higher
levels of IgG response than rLaSota-NV ORF2 and rLaSota-NV
ORF2þ3þ30UTR in immunized mice (po0.05). Therefore, our
results suggest that rBCm-NV ORF2þ3þ30UTR induced similar
levels of IgG response compared to that induced by puriﬁed
baculovirus-expressed VLPs in mice.
The systemic NV-speciﬁc IgG response was further character-
ized into Th1 and Th2 responses by measuring IgG antibody
subtypes IgG2a and IgG1, respectively (Fig. 3C and D). The
baculovirus-expressed VLPs induced the highest level of IgG1
subtype (po0.05), resulting in a Th2/Th1 ratio of 2.5. In contrast,
both rLaSota and rBCm containing ORF2þ3þ30UTR induced high
levels of IgG2a response compared to rLaSota-NV ORF2 and
baculovirus-expressed VLPs (po0.05), resulting in a Th1/Th2 ratio
of 3.5 and 6.3, respectively. This result suggests a difference in
induction of systemic NV-speciﬁc immune response between live
NDV vaccines and nonreplicating baculovirus VLPs.
This was further evaluated by measuring speciﬁc cellular
immune response from mouse splenocytes (Fig. 3E). At 6 wpi,
the spleens were collected from sacriﬁced mice for detection of
IFN-γ, TNF-α, and IL-2 levels by a cytokine speciﬁc enzyme-linked
immunospot (ELISPOT) assay. Among the immunized groups,
rBCm-NV ORF2þ3þ30UTR produced the highest levels of IFN-γ,
IL-2, and TNF-α (po0.005). In contrast, rLaSota-NV ORF2 and
baculovirus-expressed VLPs induced low levels of the three
cytokines compared to rBCm-NV ORF2þ3þ30UTR (po0.05).
Mucosal immune response in mice was evaluated by determin-
ing IgA titers by ELISA in the collected fecal samples at 5 and 6 wpi
(Fig. 3F). The level of IgA was calculated from a standard curve that
was determined by the absorbance values of the mouse IgA
standard. rBCm-NV ORF2þ3þ30UTR induced signiﬁcantly higher
levels of IgA responses than those induced by baculovirus-
expressed VLPs and other rNDVs (po0.05). Baculovirus-
expressed VLPs induced higher IgA response than rLaSota-NV
ORF2 and rLaSota-NV ORF2þ3þ30UTR (po0.05).
Discussion
NDV has shown promising results as a potential vaccine vector
for human use (Bukreyev and Collins, 2008). We show here that
the NDV vector can provide an alternative live vaccine platform for
noroviruses and other non-cultivable pathogens of humans.
Although both lentogenic and mesogenic NDV strains can be used
as vaccine vectors, the mesogenic strains are more easily grown
in vitro and are more immunogenic in vivo (Bukreyev et al., 2005).
In our previous study, we expressed the VP1 protein of human
norovirus (GII.4) using conventional rLaSota and rBCm vectors and
showed that rBCm vector was more efﬁcient than the rLaSota
vector in inducing humoral, cellular and mucosal immune in mice
(Kim et al., 2014). This indicated that rBCm has the potential to be
a vaccine vector against norovirus infection in humans.
Previously, the expression of VP1 by baculovirus in insect cells
was enhanced by the presence of the ORF3 and NV 30UTR
(Bertolotti-Ciarlet et al., 2003). These sequences located at the 30
end of the NV genome contain cis-acting regulatory elements that
are required for gene expression and translational regulation.
Similarly, in this study, insertion of only ORF2 into rLaSota and
rBCm vectors resulted in weak levels of expression of VP1 protein
in DF1 cells and in allantoic ﬂuid of embryonated chicken eggs.
However, inclusion of ORF3 and 30UTR in our NDV constructs
enhanced the level of VP1 expression in DF1 cell lysates, in cell
culture medium, and in allantoic ﬂuid of embryonated chicken
eggs. Furthermore, morphological analysis of VLPs produced by
the two rNDV vectors showed similarity to those produced by the
baculovirus expression system. Our study suggests that rNDV
vector can produce large quantities of VLPs in embryonated
chicken eggs at 3 dpi compared to baculovirus-expressed VLPs in
insect cells at 7 dpi. Therefore, NDV vector can be a cost-effective,
efﬁcient, time-saving, and feasible approach for large-scale man-
ufacture of various genotypes of norovirus VLP vaccines.
NV VLP vaccines have been immunogenic in animal models via
parenteral, oral, or intranasal route (Guerrero et al., 2001). A NV
VLP vaccine was evaluated in a phase II human trial, showing that
a two-dose, intranasally administered NV VLP vaccine (100 mg)
with adjuvants provided homologous protection against NV-
associated viral gastroenteritis (Atmar et al., 2011). Human trial
study suggests that the induction of IFN-γ and IgG2a antibody
levels by VLP immunization can be important for efﬁcient pre-
vention of norovirus infection. Although the early norovirus
vaccine trials appear promising (Ramani et al., 2014), there also
exist several challenges to vaccine, such as large-scale manufac-
ture of VLP vaccines and their protective efﬁcacy against a broad
range of norovirus strains. In general, the magnitude of the
immune response to live viral vaccines over subunit protein or
inactivated virus vaccines is substantially greater and broader in
primary immunization (Belshe et al., 2007). Our previous study
also supports the advantage of vaccination with live rNDVs
expressing norovirus VP1 proteins over nonreplicating VLPs (Kim
et al., 2014). In this study, optimization of VP1 protein expression
by NDV was crucial to enhance the immunogenicity of rNDV-
vectored vaccine for norovirus. As observed in our mouse study,
expression of ORF2 in the presence of ORF3 and 30UTR induced
higher levels of immune response than that of ORF2 alone in the
transcription unit, indicating that the amount of VP1 expression
greatly affected the immune response in mice. VP2 might play a
role in stabilization of VLPs (Bertolotti-Ciarlet et al., 2003).
Although both rNDV vectors induced similar levels of IgG immune
response, rBCm-NV ORF2þ3þ30UTR induced higher levels of IgA
and speciﬁc cellular immune responses than rLaSota-NV
ORF2þ3þ30UTR in mice, indicating that the NDV vector backbone
can play an important role in induction of immune response. Our
studies have also demonstrated that the expression of norovirus
capsid proteins, GI and GII.4 did not increase NDV virulence for
chickens; thus, showing the potential of a safe and effective
vaccine for control of norovirus infection. In future studies, we
will explore the protective efﬁcacy of rNDV vectored vaccines
expressing genotype GI and GII.4 VP1 proteins. It may be possible
to formulate a bivalent vaccine for broad protection against
norovirus infection.
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Materials and methods
Generation of rNDVs expressing NV VP1 protein
The position between the P and M genes in the rNDV genome
has been identiﬁed as the optimal location for expression of
foreign genes without affecting replication of rNDV (Bukreyev
and Collins, 2008). Therefore, the ORF2 (1593 nt) of Norovirus
strain Norwalk virus (Hu/NV/Norwalk virus/1968/US) (Fernandez-
Vega et al., 2004) was inserted into the intergenic region between
the P and M genes in antigenomic cDNAs of NDV strain rLaSota
and a modiﬁed strain rBC (Fig. 1). In addition, an expression
cassette containing NV ORF2, ORF3, and 30UTR (2297 nt) was
placed into cDNA of rLaSota and rBCm vectors as described above.
rNDVs were recovered using our standard procedure (Huang et al.,
2001). The recovered recombinant viruses were passaged ﬁve
times in embryonated chicken eggs and conﬁrmed by RT-PCR
and sequence analysis.
In vitro characterization of rNDVs expressing NV VP1 protein
Expression of the NV VP1 protein in DF1 cells and in embryo-
nated chicken eggs was analyzed by Western blot using a mono-
clonal antibody to VP1. The ability of rNDV vectors to produce VLPs
in embryonated eggs was evaluated by puriﬁcation of the VLPs by
CsCl isopycnic gradient (1.36 g/cm3) ultracentrifugation and by
negative-staining EM analysis (Vongpunsawad et al., 2013). To
verify the morphology of VLP produced using the NDV system, the
ORF2 of NV (Hu/NV/Norwalk virus/1968/US) was cloned into
bacmids and transfected into S. frugiperda (Sf9) cells (Invitrogen).
Baculovirus-expressed VLPs were puriﬁed and compared with
VLPs produced by the NDV system.
The multicycle growth kinetics of rNDVs was evaluated in DF1
cells in the presence of 10% chicken egg allantoic ﬂuid. Pathogenicity
of rNDVs expressing NV VP1 protein was determined by the MDT in
9-day-old speciﬁc pathogen free (SPF) embryonated chicken eggs and
by the ICPI test in 1-day-old SPF chicks (Alexander, 1989).
Immunogenicity of rNDVs expressing NV VP1 protein in mice
Groups of four-week-old female BALB/c mice (5 mice per
group) were immunized with rLaSota-NV ORF2, rLaSota-NV
ORF2þ3þ30UTR, or rBCm-NV ORF2þ3þ30UTR (30 ml of each,
106 EID50) by the intranasal route after inhalational anesthesia.
One group of mice was intranasally inoculated with 30 μg of
baculovirus-expressed VLPs (Fang et al., 2013). Mice received three
doses of immunization with two-week intervals. The last group of
mice was inoculated with PBS as unvaccinated controls. Serum and
fecal samples were collected from pre-immunized mice and
immunized mice at 5 and 6 week postinoculation (wpi). To
evaluate antibody-mediated neutralization, HBGA binding block-
ing assay was conducted by measuring the ability of serum
antibodies to inhibit NV VLP binding to H type 1 and Lewis b
antigens (Reeck et al., 2010; Lindesmith et al., 2012). VLP binding
to carbohydrates in the absence of a serum sample was used as a
positive control. For each sample, the 50% blocking titer (BT50) was
deﬁned as the titer at which the OD reading (after subtraction of
the blank) was 50% of the OD of the positive control. NV-speciﬁc
IgG, IgG1, IgG2a, and IgA titers in serum were measured by an
enzyme-linked immunosorbent assay (ELISA) (Ball et al., 1998;
Fang et al., 2013). At 6 wpi, the spleens were collected from
sacriﬁced mice for detection of IFN-γ, TNF-α, and IL-2 levels by a
cytokine speciﬁc enzyme-linked immunospot (ELISPOT) assay
(Lindesmith et al., 2005). The results are expressed as mean
spot-forming cells (SFC) per 106 splenocytes of duplicate wells.
Stool samples were analyzed for NV-speciﬁc and total IgA by ELISA
(Ball et al., 1998). The level of IgA was calculated from a standard
curve that was determined by the absorbance values of the mouse
IgA standard. Fecal IgA responses were expressed as a ratio of the
NV-speciﬁc IgA (ng/ml) to total IgA (μg/ml). Statistically signiﬁcant
differences in immune responses between immunized mouse
groups (po0.05) were evaluated by one-way analysis of variance
(ANOVA).
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